A reassuring collection of quotes. The key one being the contrast between revenue and ebitda growth showing the operating leverage that should still drive profit growth in excess of revenue growth.
The signs are that this is a tax related sell-down, though I have no idea why.
It is a little concerning given that Editure have expertise in the industry, but it could also have to do with the fact that Editure sees its interest in KME as limiting its own business opportunities in some way.
A reassuring collection of quotes. The key one being the...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add KME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.00M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 52617 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 13091 | 1 |
View Market Depth
| Last trade - 16.12pm 21/11/2024 (20 minute delay) ? |
| KME (ASX) Chart |
Day chart unavailable
